(Circulation. 2001;103:2681.)
© 2001 American Heart Association, Inc.
Clinical Investigation and Reports |
Immunohistological Changes in Dilated Cardiomyopathy Induced by Immunoadsorption Therapy and Subsequent Immunoglobulin Substitution
From the Klinik für Innere Medizin B, Ernst-Moritz-Arndt-Universität, Greifswald (A.S., S.B.F.); the Institut für Pathologie (F.S.), Medizinische Klinik I (V.S., M.B., K.S., G.B.), Institut für Experimentelle Endokrinologie (A.P.), and Institut für Medizinische Biometrie (K.D.W.), Charité, Humboldt-Universität, Berlin; the Institut für Pathologie und Dermatohistologie, Diagnostisches Zentrum, Berlin (K.M.); and the Max Delbrück Zentrum für Molekulare Medizin, Berlin-Buch (G.W.), Germany.
Correspondence to Alexander Staudt, MD, Klinik für Innere Medizin B, Ernst-Moritz-Arndt-Universität, Loefflerstraße 23a, 17487 Greifswald, Germany. E-mail staudt{at}mail.uni-greifswald.de
Background—Immunoadsorption (IA) and subsequent immunoglobulin (Ig) G substitution represent an additional therapeutic approach in dilated cardiomyopathy (DCM). It remains to be elucidated whether this treatment modulates myocardial inflammation, which is possibly a causal factor of ventricular dysfunction.
Methods and Results—From 25 DCM patients (EF <30%), 12 patients were randomized for IA therapy and subsequent IgG substitution at 1-month intervals until month 3. Before (<7 days) and after IA therapy, right ventricular biopsies were obtained from all patients. Biopsies were also obtained at intervals of 3 months from 13 patients without IA/IgG treatment (controls). IA/IgG treatment induced improvement in left ventricular ejection fraction from 21.3±1.7% (±SEM) to 27.0±1.3% (P<0.01 versus baseline/controls) and reduction of the ß-receptor autoantibody serum levels (P<0.01 versus baseline/controls). The number of CD3 cells decreased from 5.7±0.8 to 2.9±0.5 cells/mm2 (P<0.01 versus baseline/controls). This decline was paralleled by a decrease in CD4 (P<0.01 versus baseline/controls) and CD8 (P<0.05 versus baseline/controls) lymphocytes. The number of leukocyte common antigen–positive cells (leukocytes) was reduced from 20.0±3.2 to 9.9±2.8 cells/mm2 (P<0.01 versus baseline/P<0.05 versus controls). HLA class II expression decreased from 2.1±0.7% to 1.1±0.4% (P<0.05 versus controls/baseline). The number of immunopositive cells and the expression of HLA class II in controls remained stable. In both groups, the degree of fibrosis remained unchanged.
Conclusions—IA and subsequent IgG substitution mitigate myocardial inflammation in DCM.
Key Words: cardiomyopathy • immunology
This article has been cited by other articles:
 |
|
 |
|
  Y. Matsumoto, I.-K. Park, and K. Kohyama Matrix Metalloproteinase (MMP)-9, but Not MMP-2, Is Involved in the Development and Progression of C Protein-Induced Myocarditis and Subsequent Dilated Cardiomyopathy J. Immunol., October 1, 2009; 183(7): 4773 - 4781. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Heymans, E. Hirsch, S. D. Anker, P. Aukrust, J.-L. Balligand, J. W. Cohen-Tervaert, H. Drexler, G. Filippatos, S. B. Felix, L. Gullestad, et al. Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology Eur J Heart Fail, February 1, 2009; 11(2): 119 - 129. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. M. Hess, W. McKenna, and H.-P. Schultheiss CHAPTER 18 Myocardial Disease ESC Textbook of Cardiovascular Medicine, January 1, 2009; 2(1): med-9780199566990-chapter - med-9780199566990-chapter. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. T. Cooper, K. L. Baughman, A. M. Feldman, A. Frustaci, M. Jessup, U. Kuhl, G. N. Levine, J. Narula, R. C. Starling, J. Towbin, et al. The role of endomyocardial biopsy in the management of cardiovascular disease: A Scientific Statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology Endorsed by the Heart Failure Society of America and the Heart Failure Association of the European Society of Cardiology Eur. Heart J., December 2, 2007; 28(24): 3076 - 3093. [Full Text] [PDF]
|
|
|
|
 |
|
 L. T. Cooper, K. L. Baughman, A. M. Feldman, A. Frustaci, M. Jessup, U. Kuhl, G. N. Levine, J. Narula, R. C. Starling, J. Towbin, et al. The Role of Endomyocardial Biopsy in the Management of Cardiovascular Disease: A Scientific Statement From the American Heart Association, the American College of Cardiology, and the European Society of Cardiology Endorsed by the Heart Failure Society of America and the Heart Failure Association of the European Society of Cardiology J. Am. Coll. Cardiol., November 6, 2007; 50(19): 1914 - 1931. [Full Text] [PDF]
|
|
|
|
 |
|
 L. T. Cooper, K. L. Baughman, A. M. Feldman, A. Frustaci, M. Jessup, U. Kuhl, G. N. Levine, J. Narula, R. C. Starling, J. Towbin, et al. The Role of Endomyocardial Biopsy in the Management of Cardiovascular Disease: A Scientific Statement From the American Heart Association, the American College of Cardiology, and the European Society of Cardiology Circulation, November 6, 2007; 116(19): 2216 - 2233. [Full Text] [PDF]
|
|
|
|
|
|
A. Frustaci, M. A. Russo, and C. Chimenti Myocarditis in hypertrophic cardiomyopathy: reply Eur. Heart J., July 1, 2007; 28(13): 1664 - 1664. [Full Text] [PDF]
|
|
|
|
|
|
A. Staudt, P. Eichler, C. Trimpert, S. B. Felix, and A. Greinacher Fc{gamma} Receptors IIa on Cardiomyocytes and Their Potential Functional Relevance in Dilated Cardiomyopathy J. Am. Coll. Cardiol., April 24, 2007; 49(16): 1684 - 1692. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Matsumoto, I.-K. Park, and K. Kohyama B-Cell Epitope Spreading Is a Critical Step for the Switch from C-Protein-Induced Myocarditis to Dilated Cardiomyopathy Am. J. Pathol., January 1, 2007; 170(1): 43 - 51. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. W. Magnani and G. W. Dec Myocarditis: Current Trends in Diagnosis and Treatment Circulation, February 14, 2006; 113(6): 876 - 890. [Full Text] [PDF]
|
|
|
|
 |
|
 G H Stummvoll, M Aringer, J S Smolen, S Schmaldienst, E Jimenez-Boj, W H Horl, W B Graninger, and K Derfler IgG immunoadsorption reduces systemic lupus erythematosus activity and proteinuria: a long term observational study Ann Rheum Dis, July 1, 2005; 64(7): 1015 - 1021. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Torre-Amione, F. Sestier, B. Radovancevic, and J. Young Effects of a novel immune modulation therapy in patients with advanced chronic heart failure: Results of a randomized, controlled, phase II trial J. Am. Coll. Cardiol., September 15, 2004; 44(6): 1181 - 1186. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Matsumoto, Y. Tsukada, A. Miyakoshi, H. Sakuma, and K. Kohyama C Protein-Induced Myocarditis and Subsequent Dilated Cardiomyopathy: Rescue from Death and Prevention of Dilated Cardiomyopathy by Chemokine Receptor DNA Therapy J. Immunol., September 1, 2004; 173(5): 3535 - 3541. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Staudt, Y. Staudt, M. Dorr, M. Bohm, F. Knebel, A. Hummel, L. Wunderle, M. Tiburcy, K. D. Wernecke, G. Baumann, et al. Potential role of humoral immunity in cardiac dysfunction of patients suffering from dilated cardiomyopathy J. Am. Coll. Cardiol., August 18, 2004; 44(4): 829 - 836. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M Bohm, T Dorner, F Knebel, A Bruns, N Jochmann, and G Baumann Longlasting effects of immunoadsorption in severe Sjogren's syndrome Ann Rheum Dis, February 1, 2004; 63(2): 214 - 215. [Full Text] [PDF]
|
|
|
|
|
|
M. Noutsias, M. Pauschinger, H.-P. Schultheiss, and U. Kuhl Cytotoxic perforin+ and TIA-1+ infiltrates are associated with cell adhesion molecule expression in dilated cardiomyopathy Eur J Heart Fail, August 1, 2003; 5(4): 469 - 479. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Noutsias, M. Pauschinger, H.-P. Schultheiss, and U. Kuhl Advances in the immunohistological diagnosis of inflammatory cardiomyopathy Eur. Heart J. Suppl., December 1, 2002; 4(suppl_I): I54 - I62. [Abstract] [PDF]
|
|
|
|
|
|
S.B. Felix, A. Staudt, and G. Baumann Immunoadsorption as a new therapeutic principle for treatment of dilated cardiomyopathy Eur. Heart J. Suppl., December 1, 2002; 4(suppl_I): I63 - I68. [Abstract] [PDF]
|
|
|
|
|
|
U. Kuhl, M. Pauschinger, M. Noutsias, J.-F. Kapp, and H.-P. Schultheiss Diagnosis and treatment of patients with virus induced inflammatory cardiomyopathy Eur. Heart J. Suppl., December 1, 2002; 4(suppl_I): I73 - I80. [Abstract] [PDF]
|
|
|
|
|
|
A. Staudt, M. Bohm, F. Knebel, Y. Grosse, C. Bischoff, A. Hummel, J. B. Dahm, A. Borges, N. Jochmann, K. D. Wernecke, et al. Potential Role of Autoantibodies Belonging to the Immunoglobulin G-3 Subclass in Cardiac Dysfunction Among Patients With Dilated Cardiomyopathy Circulation, November 5, 2002; 106(19): 2448 - 2453. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. B. Felix, A. Staudt, M. Landsberger, Y. Grosse, V. Stangl, T. Spielhagen, G. Wallukat, K. D. Wernecke, G. Baumann, and K. Stangl Removal of cardiodepressant antibodies in dilated cardiomyopathy by immunoadsorption J. Am. Coll. Cardiol., February 20, 2002; 39(4): 646 - 652. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. G. Mahon, B. P. Madden, A. L. P. Caforio, P. M. Elliott, A. J. Haven, B. E. Keogh, M. J. Davies, and W. J. McKenna Immunohistologic evidence of myocardial disease in apparently healthy relatives of patients with dilated cardiomyopathy J. Am. Coll. Cardiol., February 6, 2002; 39(3): 455 - 462. [Abstract] [Full Text] [PDF]
|
|